Skip to main content

Table 2 Concentrations (U/ml) (median values (IQR)) of anti-CCP2 antibodies in pre-patients, matched controls and RA patients

From: Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis

 

IgA-CCP2

IgG-CCP2

IgM-CCP2

Controls (n = 276)a

0.8

1.2

18.5

(IQR)

(0.5 to 1.1)

(0.8 to 2.1)

(11.1 to 34.3)

Pre-patients (n = 71)b

1.1*

3.4 **

21.6 *

(IQR)

(0.6 to 2.1)

(1.2 to 55.0)

(10.1 to 55.3)

Patients (n = 53)c

1.8***

14.0 ***

51.9***

(IQR)

(0.9 to 6.8)

(11.4 to 715.5)

(29.8 to 127.0)

p value1

<0.001

<0.001

<0.001

  1. a Analysis of IgM; n = 263 controls b, Analysis of IgM; n = 68 pre-patient samples, cAnalysis of IgA; n = 54 and of IgG-CCP2; n = 59, * P < 0.05, ** P < 0.01, ***P < 0.001 pre-patients vs. controls or RA patients vs. controls,1P-values obtained from Kruskal-Wallis analysis comparing all three groups. Anti-CCP, anti-cyclic citrullinated peptide; IQR, inter quartile range; Ig, immunoglobulin.